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Inoperable non-small-cell lung cancer (NSCLC): a Medical Research
Council randomised trial of palliative radiotherapy with two fractions or
ten fractions
Report to the Medical Research Council by its Lung Cancer Working Party'
Summary Two policies of palliative thoracic radiotherapy for non-small-cell lung cancer have been compared
in a randomised multicentre controlled trial. A total of 369 patients with inoperable, histologically or
cytologically confirmed disease, too advanced for radical 'curative' radiotherapy, and with their main symp-
toms related to the primary intrathoracic tumour even if metastases were present, were studied. They were
allocated at random either to a regimen of 17 Gy given in two fractions of 8.5 Gy 1 week apart (F2 regimen),
or to a conventional multifractionated regimen of either 30 Gy in ten fractions or 27 Gy in six fractions (a
biologically equivalent dose), given daily except at weekends (FM regimen). On admission, 93% of the patients
had cough, 47% haemoptysis, 57% chest pain, 58% anorexia, and 11% dysphagia. As assessed by the
clinicians, palliation of the main symptoms was achieved in high proportions of patients ranging in the F2
group from 65% for cough to 81% for haemoptysis and in the FM group from 56% for cough to 86% for
haemoptysis. Haemoptysis, chest pain, and anorexia disappeared for a time in well over half the patients with
these symptoms, and cough in 37%. For all the main symptoms, the median duration of palliation was 50%
or more of survival. Performance status improved in approximately half of the patients with a poor status on
admission. All these results were similar in the two treatment groups.
As assessed daily by the patients using a diary card, the quality of life deteriorated slightly during treatment
but then improved steadily during the next 5 weeks. The proportion of patients with dysphagia increased
considerably during treatment, but fell to the pretreatment level during the next 2 weeks. The results were
similar in the two groups. Radiation myelopathy was suspected in one (F2) patient.
There was no difference in survival between the two groups (log-rank test), the median survival time from
the date of allocation being 179 days in the F2 and 177 days in the FM group. In the light of all the findings,
the regimen of two fractions of 8.5 Gy given I week apart is recommended.
Only a small proportion of patients with inoperable stage I
or II non-small-cell lung cancer are cured by primary radio-
therapy (Perez et al., 1982; Komaki et al., 1985). The
majority present with tumour too advanced for radical radio-
therapy, but require palliative treatment for major symptoms
related to intrathoracic tumour (Carroll et al., 1986). It is
usual to treat such patients, either at first presentation or
when significant symptoms develop, with a course of palli-
ative radiotherapy (Mulshine et al., 1986).
The palliative radiotherapy schedule varies considerably in
different centres, but in the United Kingdom a typical course
would be a dose of 30 Gy given in ten fractions over 2 weeks
(Carroll et al., 1986). The present study was conducted to
find out whether a shorter course comprising only two frac-
tions of 8.5 Gy (total dose 17 Gy) given 1 week apart gives
equally good palliation in the treatment of patients with
inoperable non-small-cell lung cancer whose main symptoms
are related to intrathoracic tumour. Much of a radiotherapy
practice is based on cumulative experience. These two regi-
mens were selected from the experience of members of the
working party. If the two-fraction regimen proved effective, it
would involve patients in only two attendances for treatment,
and would greatly reduce the cost in terms of machine-time
and staff.
Methods
Eligibility
Patients of either sex and any age were eligible if they had
previously untreated, inoperable, histologically or cyto-
logically proved lung cancer of any histological type except
small-cell as diagnosed by the local histopathologist; disease
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considered by the local radiotherapist to be too advanced for
'curative' or long-term palliative radiotherapy; were expected
to survive for at least 1 month from admission, and had their
main symptoms related to the primary intrathoracic tumour,
even if metastases were present. Before a centre entered a
patient into the study, local ethics committee approval of the
protocol and individual patient consent were obtained.
The diagnoses were made by the histopathologists from the
referring centres according to the WHO classification (World
Health Organization, 1981). The specimens were later exam-
ined by a single reference histopathologist for confirmation
of the cell type, and the majority of the specimens by at least
one other reference histopathologist.
Pretreatment investigations
The pretreatment investigations included clinical examina-
tion, a postero-anterior chest radiograph, measurement of the
blood haemoglobin concentration, and total white cell and
platelets counts. Evidence of superior vena cava obstruction
was recorded when present.
Treatment allocation
Clinicians telephoned the Trials Office and patients were
allocated to one or other of two treatment regimens using a
minimisation procedure (Pocock, 1983), stratifying for histo-
logical type and admitting radiotherapist.
Two-fraction regimen (F2 regimen) The patients allocated
to the F2 regimen were given megavoltage radiotherapy to a
total midline dose of 17 Gy, calculated without air correc-
tion, in two fractions of 8.5 Gy I week apart.
Multi-fractionated regimen (FM regimen) The patients allo-
cated to the FM regimen were given megavoltage radio-
therapy to a total midline dose of 30 Gy, calculated without
air correction, in ten fractions 5 days per week over 2 weeks,
or the biologically equivalent dose of 27 Gy in six fractions,
treatment being given daily except at week-ends. The choice
of 30 or 27 Gy was left to the individual radiotherapist.
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In both treatment groups, the radiotherapy was delivered
through opposing portals to the primary site and mediastinal
lymph nodes. The field included the loco-regional tumour
volume with a margin of not more than 1 cm, the total area
not exceeding 200 cm2. Concurrent steroid administration
was recommended for patients with superior vena cava ob-
struction, but was also permitted in other patients.
Reports and investigations
A progress report on each patient was completed monthly up
to 12 months and then once every 3 months. These reports
included details of the treatment given, the local response to
treatment according to the WHO definitions (World Health
Organization, 1979), adverse effects encountered, details of
any metastases, and the blood haemoglobin concentration
and total white cell and platelet counts. At death, the certi-
fied cause was reported and, if an autopsy was done, the
findings.
Assessment ofpalliation by clinicians
The clinician's assessment of the patient's overall condition,
level of physical activity, and degree of breathlessness were
recorded at each attendance according to the categories
shown in Table I. The clinician also asked the patient about
the occurrence and severity, since the last attendance, of the
symptoms listed in Table II, and of pain in other sites,
nausea, vomiting, sore throat, diarrhoea, and other symp-
toms, recording the answers as none, mild, moderate, or
severe. Details of the management of symptoms and adverse
effects of radiotherapy were recorded.
Daily assessment by patients
For their first 6 months in the study, the patients completed
an MRC patient diary card, similar to that described by
Table II Main symptoms on admission as recorded by the
clinicians
F2 FM Total
Symptom No. (%) No. (%) No. (%)
Cough
none 12 (7) 15 (8) 27 (7)
mild 83 (45) 95 (52) 178 (48)
moderate 80 (43) 68 (37) 148 (40)
severe 9 (5) 6 (3) 15 (4)
Haemoptysis
none 99 (54) 97 (53) 196 (53)
mild 56 (30) 56 (30) 112 (30)
moderate 24 (13) 28 (15) 52 (14)
severe 5 (3) 3 (2) 8 (2)
Chest pain
none 82 (45) 78 (42) 160 (43)
mild 66 (36) 69 (38) 135 (37)
moderate 33 (18) 33 (18) 66 (18)
severe 3 (2) 4 (2) 7 (2)
Anorexia
none 75 (41) 78 (42) 153 (42)
mild 69 (38) 70 (38) 139 (38)
moderate 34 (19) 31 (17) 65 (18)
severe 4 (2) 5 (3) 9 (2)
Dysphagia
none 163 (89) 164 (89) 327 (89)
mild 15 (8) 16 (9) 31 (8)
moderate 4 (2) 4 (2) 8 (2)
severe 1 (1) 0 (0) 1 (< 1)
Depression
none 139 (76) 133 (73) 272 (75)
mild 37 (20) 41 (23) 78 (21)
moderate 5 (3) 7 (4) 12 (3)
severe 1 (1) 1 (1) 2 (1)
Anxiety
none 68 (37) 72 (40) 140 (38)
mild 91 (50) 83 (46) 174 (48)
moderate 21 (12) 26 (14) 47 (13)
severe 2 (1) 1 (1) 3 (1)
Table I General characteristics of the patients on admission
F2 FM Total
Characteristic No. (%) No. (%) No. (%)
Sex: male 145 (79) 144 (78) 289 (78)
Age (years):
-44 1 (1) 1 (1) 2 (1)
45-54 10 (5) 7 (4) 17 (5)
55-64 46 (25) 41 (22) 87 (24)
65-74 93 (51) 90 (49) 183 (50)
75 + 34 (18) 46 (25) 80 (22)
Histology (assessed locally)
squamous 147 (80) 147 (79) 294 (80)
adenocarcinoma 15 (8) 16 (9) 31 (8)
large-cell 14 (8) 14 (8) 28 (8)
undifferentiated 5 (3) 6 (3) 11 (3)
untyped 3 (2) 2 (1) 5 (1)
Superior vena cava obstruction present 4 (2) 8 (4) 12 (3)
Distant metastases 59 (32) 60 (32) 119 (32)
Overall condition:
1. Excellent 10 (5) 8 (4) 18 (5)
2. Good 70 (38) 63 (34) 133 (36)
3. Fair 84 (46) 93 (51) 177 (48)
4. Poor 20 (11) 20 (11) 40 (11)
5. Very poor 0 (0) 0 (0) 0 (0)
Level of physical activity:
1. At work or active retirement 15 (8) 14 (8) 29 (8)
2. Full activity but not at work 75 (41) 83 (45) 158 (43)
3. Out and about, but activity restricted 72 (39) 67 (36) 139 (38)
4. Confined to home or hospital 20 (11) 17 (9) 37 (10)
5. Confined to bed 1 (1) 3 (2) 4 (1)
Degree of breathlessness:
1. Climbs hills or stairs without dyspnoea 17 (9) 12 (7) 29 (8)
2. Walks any distance on flat without 45 (24) 38 (21) 83 (23)
dyspnoea
3. Walks over 100 yards without 48 (26) 67 (37) 115 (31)
dyspnoea
4. Dyspnoea on walking 100 yards or less 53 (29) 42 (23) 95 (26)
5. Dyspnoea on mild exertion, 21 (11) 24 (13) 45 (12)
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Fayers and Jones (1983). Every evening after their last meal,
they recorded how they had been feeling during the past
24 h, coding their assessments as follows:
Nausea 1, none; 2, mild; 3, moderate; 4, severe.
Vomiting 1, none; 2, sick once; 3, sick two or three times; 4,
sick four or more times.
Difficulty in swallowing 1, none; 2, mild soreness only; 3,
can swallow solids with difficulty; 4, cannot swallow solids; 5,
cannot swallow liquids.
Activity 1, normal work/housework; 2, normal work but
with effort; 3, reduced activity but not confined to home; 4,
confined to home or hospital; 5, confined to bed.
Mood 1, very happy; 2, happy; 3, average; 4, miserable; 5,
very miserable.
Overall condition 1, very well; 2, well; 3, fair; 4, poor; 5,
very ill.
Patients did not record other symptoms on their diary
cards.
Statistical methods
Palliation of a particular symptom as recorded by clinicians
was expressed as the proportion of patients with an improve-
ment of at least one grade on the relevant scale. Duration of
palliation was expressed in two ways: (i) as the median
duration of palliation and (ii), because of the variable dura-
tion of survival, as the percentage of survival time during
which there was palliation. The log-rank test was used to test
for differences in survival curves. The effect of various risk
factors on survival was assessed by a proportional hazards
regression model as described by Pocock (1983). The trial
data were managed using the COMPACT program (Chilvers
et al., 1988).
Results
Patients in the study
Between March 1985 and February 1988, 374 patients were
randomised from 14 centres in the United Kingdom. Five
patients were excluded because they were ineligible and had
been admitted in error. There remain 369 (184 F2, 185 FM)
patients for analysis on an intention to treat basis. All had
non-small-cell lung cancer diagnosed locally but in 15 (4%)
the subsequent reference histopathological assessment was
small-cell lung cancer.
On admission (Table I), 71% of the patients were aged 65
years or over; 80% had a squamous cell tumour; 3% had
superior vena cava obstruction; 32% were reported to have
distant metastases suspected or confirmed; 59% were assessed
by the clinician as being in fair or poor condition; in 49% the
level of physical activity was reduced, and 69% were report-
ed to have dyspnoea of grade 3 or worse. The distributions
of all these variables were similar in the two treatment
groups.
Nearly all (93%) of the patients had cough (Table II),
moderate or severe in 163 (44%), and 47% had haemoptysis,
57% chest pain, 58% anorexia, and 11% dysphagia. Depres-
sion was reported by 25%, 62% complained of anxiety,
although this was moderate or severe in only 14%. Nausea,
vomiting, and sore throat were uncommon.
Radiotherapy received
F2 regimen Of the 184 F2 patients, 170 (92%) received their
radiotherapy according to the protocol, four with minor
deviations. Of the remaining 14, eight were given the FM
regimen in error, one was given 23 Gy in three fractions, and
the remaining five were given the first fraction only: three
died before the second was given, one refused the second,
and one was not given the second because of intercurrent
illness.
FM regimen Of the 185 FM patients, 175 (95%) received
their radiotherapy according to the protocol (126 receiving
30 Gy and 49 27 Gy). Of the remaining ten, seven did not
complete the course (four because they died and three
because of clinical deterioration), one was given 40 Gy in ten
fractions, one 23 Gy in five fractions, and one 20 Gy in five
fractions.
Additional thoracic radiotherapy Only nine of the F2 and 12
of the FM patients were given additional thoracic radio-
therapy after completion of their allocated regimen.
Treatment other than radiotherapy
Data on treatment other than radiotherapy were not formally
collected by means of specific direct questions, but clinicians
were asked to record their 'management of symptoms and
adverse reactions'. By this means it was known that at least
52 F2 and 48 FM patients were treated with analgesics, and
50 and 55 with steroids and ten and 11 with bronchodilators,
respectively. It is likely that these medicaments contributed to
palliation, but there was no difference between the treatment
groups.
Palliation ofmain symptoms as assessedby clinicians
Palliation of a symptom was defined as disappearance of the
symptom or improvement by one or more categories (from
mild to none, from moderate to mild or none, or from severe
to moderate, mild or none), at one or more assessment.
Palliation of the main symptoms (Table III) was achieved in
high proportions of patients, ranging in the F2 group from
65% for cough to 81% for haemoptysis and in the FM
group from 56% for cough to 86% for haemoptysis. More-
over, haemoptysis, chest pain, and anorexia disappeared for
a time in well over half the patients with these symptoms in
both groups, and cough in 37% of the F2 and 37% of the
FM patients. Also, depression and anxiety were ameliorated
in a high proportion of patients in each group.
The numbers of patients with moderate or severe symp-
toms are shown in Table II. In these patients, cough was
palliated in 73 (82%) of the F2 and 55 (74%) of the FM
patients, and haemoptysis in 26 (90%) and 27 (87%), chest
pain in 27 (75%) and 27 (73%), and anorexia in 26 (68%)
and 20 (56%), respectively. The numbers in whom symptoms
disappeared were, in the two groups respectively, 28 (31%)
and 22 (30%) for cough, 24 (83%) and 25 (81%) for haemo-
ptysis, 18 (50%) and 20 (54%) for chest pain and 15 (39%)
and 14 (39%) for anorexia. Thus, as might be predicted
because palliation was defined as improvement by one or
more categories, in patients with moderate or severe symp-
toms, the proportions with palliation were higher than in
those with mild symptoms, but the proportions in whom
symptoms disappeared were lower.
The proportions of patients in whom palliation was
achieved and in whom symptoms disappeared were similar in
the F2 and FM groups, whatever the severity of the symp-
toms.
Duration ofpalliation as assessed by clinicians
The duration of palliation as assessed by the clinicians is
shown in Table III in two ways: (i) as the median time in
palliation, and (ii), because of the variable duration of sur-
vival, as the median percentage of survival time in the first
year during which there was palliation. The median time in
palliation ranged in the F2 group from 69 days for chest pain
to 146 for haemoptysis, and in the FM group from 71 days
for anorexia to 140 for haemoptysis. For all six of the main
symptoms the median duration of palliation was 50% or
more of survival, or of the first year in patients who survived
longer. The findings in the F2 and FM groups were similar.
A comparison ofpatients who survived 6 months or less with
those who survived longer showed that duration of survival
had no consistent effect on the median proportion of survival
during which there was palliation.268 MRC LUNG CANCER WORKING PARTY
Table III Palliation of main symptoms as assessed by clinicians
Patients in Patients withpalliation
No. of Patients whom Median time Median % ofsurvival in
patients with with symptom in palliation palliation in thefirst year
symptom palliation disappeared Interquartile Interquartile
Symptom Regimen pretreatment No. (%) No. (%) Days range (%) range
111 (65)
95 (56)
69 (81)
75 (86)
77 (75)
85 (80)
73 (68)
68 (64)
31 (72)
28 (57)
81 (71)
73 (66)
63 (37)
62 (37)
67 (79)
73 (84)
68 (67)
78 (74)
62 (58)
62 (58)
29 (67)
27 (55)
75 (66)
68 (62)
71
7
14
14
6
7
7
7
9
10
8
8
r0 42-116 (50) (29-73)
F8 35-150 (50) (28-81)
[6 49-189 (76) (62-89)
.0 74-256 (84) (68-91)
9 45-170 (64) (36-78)
4 38-140 (50) (35-79)
78 39-129 (50) (35-69)
11 34-171 (50) (28-76)
11 39-126 (68) (50-75)
4 41 -149 (62) (37-78)
0 38-181 (50) (35-78)
9 40- 140 (62) (46-76)
Table IV Clinicians' assessment of performance status
Patients with improvement
Median time Median % ofsurvival
Patients with improved time improved
grade 3 or worse Interquartile Interquartile
Assessment Regimen on admission No. (%) Days range (%) range
Overall F2 104 46 (44) 68 35- 148 (50) (31-72)
condition FM 113 45 (40) 83 36- 124 (45) (28-62)
Physical F2 93 45 (48) 80 45- 146 (50) (33-73)
activity FM 87 36 (41) 99 63- 181 (54) (41 -77)
Degree of F2 122 80 (66) 72 31-133 (50) (30-72)
breathlessness FM 113 76 (57) 88 44- 139 (50) (35-64)
For definitions see Table I.
Performance status as assessed by clinicians
The clinicians assessed performance status in terms of general
condition, level of physical activity, and degree of breathless-
ness (Table IV). On these three criteria, performance status
among patients with grade 3 or worse (defined in Table I) on
admission improved in 44%, 48% and 66% respectively of
the F2 patients, and 40%, 41% and 57% of the FM patients.
The median proportion of the survival period in the first year
during which the performance status was better than on
admission was, in the F2 group, 50% for overall condition,
50% for level of physical activity, and 50% for degree of
breathlessness, the corresponding figures for the FM group
being 45%, 54% and 50%, respectively. Thus, the results
were similar in the two treatment groups.
Compliance in the use ofpatient diary cards
Patients were asked to complete their patient diary cards
every day during the first 6 months of the study. Compliance
in providing the data requested was calculated on this basis
but excluding the last 4 weeks of life in patients who died
before 7 months. In all, 175 (47%) of the 369 patients
provided between 76 and 100% of the data requested, 58
(16%) provided 51-75%, 45 (12%) provided 26-50%, 15
(4%) provided 1-25% and the remaining 76 (21%) provided
no data at all. Similarly, five (36%) of the 14 centres pro-
vided 76-100%, seven (50%) provided 51-75%, one (7%)
provided 26-50%, and one (7%) provided 1-25%. Thus
63% of the patients and 86% of the centres provided at least
half of the data requested. There was evidence that perfor-
mance status on admission affected compliance. Thus, 74%
of the data was obtained from 187 patients with their level of
physical activity grade 1 or 2 on admission compared with
63% from the 180 with grade 3, 4, or 5 (for definitions of
grades see Table I).
Day-to-day changes recorded by patients on the patient diary
cards
The patient diary cards proved to be sensitive to day-to-day
changes. Thus, the percentage of patients reporting a level of
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Figure 1 Percentage of patients reporting a level of physical
activity of grade 3 or worse on their diary cards; based on
between 122 and 86 F2 and 131 and 96 FM ---patients.
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Figure 2 Percentage of patients reporting dysphagia of grade 3
or worse on their diary cards; based on between 122 and 87 F2
and 133 and 98 FM --- patients.
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physical activity of grade 3 or worse on any one day (Figure
1), rose slightly, from about 65% to about 75%, during
treatment, then fell steadily during the next 5 weeks, the
findings being similar in the two treatment groups. Broadly
similar results were seen for mood and overall condition, the
findings for the two groups again being very similar (details
not shown). Little nausea or vomiting was recorded at any
time.
In marked contrast, the percentage of patients reporting
dysphagia of grade 3 or worse on any one day (Figure 2)
rose from about 5% to about 40% during treatment, and fell
to the pretreatment level again during the next 2 weeks,
remaining unchanged thereafter. This was thus an adverse
effect of radiotherapy, and the findings were similar in the
two groups.
Suspected radiation myelopathy in onepatient
Radiation myelopathy was suspected in one (F2) of the 374
patients admitted to the study. He had a squamous cell
tumour and received his two doses of 8.5 Gy as allocated
(field 10 x 12cm2), with disappearance of his two main
symptoms (cough and anorexia) and reduction in the size of
his intrathoracic tumour. Six months later he had a new
primary carcinoma of the prostate resected transurethrally.
Otherwise he remained well until 8 months after his thoracic
radiotherapy when severe weakness in the legs developed,
with a sensory level at T12 on the left and LI on the right
and sphincter disturbances. A diagnosis ofprobable radiation
myelopathy was made. The estimated cord dose was about
20 Gy; the level of transection was towards the lower end of
the radiation field. There was no evidence of spinal cord
compression and a myelogram, plain radiographs of the
spinal column, and a bone scan were all normal. He died 1
month later (38 weeks after randomisation) from broncho-
pneumonia following rapid deterioration during the previous
24 h. At autopsy, there was bronchopneumonia and persis-
tent intrathoracic tumour, but no evidence of spinal cord
compression by tumour. Histologically, the spinal cord show-
ed ascending degeneration in the cervical and most of the
thoracic segments in contrast to descending degeneration in
the lower thoracic and lumbar segments. There was no evi-
dence of irradiation damage. The brain was normal.
Local radiographic response to radiotherapy
The local radiographic response to radiotherapy was similar
in the two treatment groups. A complete response was
reported in 13 (7%) of the 184 F2 and 10 (5%) of the 185
FM patients, and a partial response in 41 (22%) and 47
(25%), respectively.
Survivalfrom allocation
The follow-up to 24 months is complete for all 369 patients.
There was no difference in survival between the two treat-
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Figure 3 Percentage of patients surviving from the date of
allocation; based on 184 F2 and 185 FM - patients.
ment groups (P = 0.8, log-rank test) (Figure 3). The median
survival was 179 days in the F2 group and 177 days in the
FM group. At 12 months, 37 (20%) F2 and 43 (23%) FM
patients were alive, and at 24 months, ten (5%) F2 and ten
(5%) FM patients.
Prognosticfactors
As this was a study of palliation, the data on prognostic
factors, together with data from other trials, will be presented
in detail elsewhere. In summary, a proportional hazards
regression model was used to investigate those factors which
may relate to survival. The pretreatment variables entered
were all those shown in Tables I and II and mentioned in
'Assessment of palliation', above, plus weight, haemoglobin
concentration, total white cell and platelet counts, site of
tumour (right or left), admitting hospital, and allocated
regimen. The most significant factor was activity status (P<
0.001, log-rank test). The median survival was 299 days
(interquartile range 178-446) for patients with grade 1
physical activity, and 206 (129-404), 154 (79-282), and 93
(42-198) days for those with grades 2, 3, 4 or 5 respectively.
Further prognostic analyses on the status of the patient at
the first assessment after radiotherapy showed that the actual
dose, fractions, and field size of radiotherapy did not signi-
ficantly affect survival.
Discussion
This study has shown that in the management of patients
with previously untreated, inoperable, non-small-cell lung
cancer, too advanced for 'curative' or long-term palliative
radiotherapy, effective palliation of the symptoms related to
intrathoracic tumour was achieved with thoracic radio-
therapy. Moreover, in a randomised comparison involving
369 patients, a regimen comprising only two fractions of
8.5 Gy given 1 week apart (total dose 17 Gy) was as effective
as a conventional multi-fractionated regimen of 30 Gy in ten
equal fractions or the biologically equivalent dose of 27 Gy
in six equal fractions, given daily except at weekends, and
was acceptable to patients. In practice, it is now to be
preferred because it involves only two attendances for treat-
ment, and is therefore much more cost-effective in terms of
machine-time and staff.
Palliation of the main symptoms was recorded by the
clinicians. At the time of admission to the study, 93% of the
patients were complaining of cough, 47% of haemoptysis,
57% of chest pain, 58% of anorexia, and 11% of dysphagia.
These proportions were obtained from a single pretreatment
assessment. It was not possible to observe patients over a
longer period pretreatment, because it would not have been
justifiable to withhold treatment solely for this purpose. On
the clinicians' assessments at clinic visits, cough was palliated
in 65% of patients in the two-fraction group and 56% in the
multiple-fraction group, the corresponding proportions for
the other main symptoms being 75% and 80% for chest pain
and 81% and 86% for haemoptysis, respectively. There was
thus a high and similar level of palliation in both treatment
groups. Indeed, symptoms disappeared altogether for a
period in high proportions of patients. Depression and anx-
iety, although assessed only crudely by single questions, were
also ameliorated. The study did not include a no-radiother-
apy control group. It is not therefore possible to determine
the extent to which palliation resulted from radiotherapy or
from other treatment, such as analgesics, steroids, and bron-
chodilators.
The duration of palliation is also important. Because of
the variable duration of survival, it was analysed not only as
the median duration of palliation but also as the median
percentage of survival time during which there was palliation.
The median duration of palliation was similar in the two
treatment groups, ranging, according to the symptom pal-
liated, from 69 to 146 days in the two-fraction group and
from 71 to 140 days in the multiple-fraction group. For all
the main symptoms, the percentage of survival time during270 MRC LUNG CANCER WORKING PARTY
which there was palliation was 50% or more, the results
being similar in the two groups. The proportions of patients
in whom general condition, level of physical activity, and
breathlessness improved were also high and similar in the
two groups. Thus, in the clinicians' assessments, substantial
improvements were obtained in both groups, not only in
specific chest symptoms but also in general well-being.
The patients were asked to complete patient diary cards on
nausea, vomiting, dysphagia, physical activity, mood and
overall condition, every day during the first 6 months of the
study; 51% or more of the requested data was received from
63% of the patients and from 86% of the centres. This level
ofcompliance was higher than in two previous studies (MRC
Lung Cancer Working Party 1989a,b) but there was evidence
that compliance was better in patients with a good perfor-
mance status on admission than in those with a poor perfor-
mance status. In spite of this, useful additional information
was obtained from the patient diary cards because of their
sensitivity to day-to-day changes. Thus, physical activity,
mood, and overall condition deteriorated transiently in both
groups during treatment, but then improved steadily during
the next 5 weeks. Both radiotherapy regimens were well
tolerated, but the patient diary cards proved to be particular-
ly valuable in documenting a transient increase in dysphagia
which occurred to a similar extent in both groups during
treatment, but then resolved rapidly, in most patients before
the clinician's assessment at 1 month. The only other impor-
tant potential adverse effect of radiotherapy occurred in the
one patient in whom a possible diagnosis of radiation myelo-
pathy was made.
In the present study and in two previous MRC studies,
both of which involved chemotherapy for small-cell lung
cancer (MRC Lung Cancer Working Party, 1989a,b), the
cards proved to be highly sensitive to day-to-day changes.
These have characteristically involved nausea and vomiting
during chemotherapy and dysphagia in the present study.
The patient diary cards generate large quantities of data.
This raises questions about how such data should be
analysed, but even when presented descriptively they can be
informative. Thus, in the present study it is important to
have shown convincingly that the degree of dysphagia, the
main adverse effect of radiotherapy, was similar in the two
treatment groups.
In the light of experience, the MRC Lung Cancer Working
Party considers that in its present studies the use of the
patient diary card is best confined to a short period during
treatment when large day-to-day changes are occurring, and
that the questions should be limited to the main symptoms of
the disease and the most important adverse effects of treat-
ment. Intermittent assessments of quality of life are also
being made by the patients using the Rotterdam symptom
check list and the Hospital Anxiety Depression scale. Such a
policy makes it possible to obtain data daily on a few
important symptoms that change from day to day and more
detailed data on a much wider variety of questions posed at
monthly or longer intervals. It also allows for an adequate
assessment of anxiety and depression, which was not
attempted in the present study.
In the present study, a local radiographic response to
radiotherapy was recorded in 29% of the patients in the
two-fraction group and in 31% in the multi-fraction group,
and survival from allocation was similar in the two groups,
showing that local tumour control was similar. In a stepwise
proportional hazards regression analysis, the level of physical
activity on admission was the factor with the greatest effect
on duration of survival. This implies that for patients with
inoperable disease and a poor performance status, purely
palliative treatment is the most appropriate management
policy. There is a case for using a more intensive radio-
therapy regimen in patients with inoperable, non-metastatic
disease and with a good performance status but with a lesion
too large in volume for radical radiotherapy with curative
intent. This is being investigated in a current MRC study.
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